UCB (STU:UNC) FCF Margin % : 13.29% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is UCB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. UCB's Free Cash Flow for the six months ended in Dec. 2023 was €354 Mil. UCB's Revenue for the six months ended in Dec. 2023 was €2,663 Mil. Therefore, UCB's FCF Margin % for the quarter that ended in Dec. 2023 was 13.29%.

As of today, UCB's current FCF Yield % is 1.88%.

The historical rank and industry rank for UCB's FCF Margin % or its related term are showing as below:

STU:UNC' s FCF Margin % Range Over the Past 10 Years
Min: 2.58 Med: 12.77 Max: 18.35
Current: 8.47

During the past 13 years, the highest FCF Margin % of UCB was 18.35%. The lowest was 2.58%. And the median was 12.77%.

STU:UNC's FCF Margin % is ranked better than
86.28% of 1035 companies
in the Biotechnology industry
Industry Median: -149.8 vs STU:UNC: 8.47

UCB FCF Margin % Historical Data

The historical data trend for UCB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB FCF Margin % Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

11.97

13.69

18.35

13.56

8.47

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															25.44	7.49	20.41	3.51	13.29

Competitive Comparison of UCB's FCF Margin %

For the Biotechnology subindustry, UCB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where UCB's FCF Margin % falls into.

UCB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

UCB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	445	/	5252
	=	8.47 %

UCB's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	354	/	2663
	=	13.29 %

UCB FCF Margin % Related Terms

Thank you for viewing the detailed overview of UCB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (STU:UNC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (STU:UNC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (STU:UNC) Headlines

No Headlines